Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | CCR8 | P51685 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 2/20 | 0.39 |
| ▸ | GCK | P35557 | 1/20 | 0.37 |
| ▸ | GCKR | Q14397 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29750782 | 0.91 | CCR1 (0.39) | CCR1CCR5CCR8HDAC6TSHR | |
| SCHEMBL12622258 | 0.86 | NPC1 (0.38) | CCR1CCR5CCR8HDAC6TSHR | |
| SCHEMBL12173603 | 0.86 | KIF11 (0.48) | TSHRLMNATYRKIF11DGAT1 | |
| SCHEMBL30492580 | 0.85 | KDM4E (0.54) | CCR1CCR5CCR8LMNARAB9A | |
| SCHEMBL13765802 | 0.85 | KDM4E (0.54) | CCR1CCR5CCR8LMNARAB9A | |
| SCHEMBL12957904 | 0.85 | RAB9A (0.37) | CCR1CCR5CCR8HDAC6TSHR | |
| SCHEMBL14062459 | 0.84 | KIF11 (0.52) | TSHRLMNATYRKIF11DGAT1 | |
| SCHEMBL45877 | 0.84 | SMN1; SMN2 (0.45) | CCR1CCR5CCR8HDAC6ALOX5AP | |
| SCHEMBL20623117 | 0.84 | ALOX5AP (0.40) | CCR1CCR5CCR8HDAC6TSHR | |
| SCHEMBL12928307 | 0.84 | ALOX5AP (0.36) | CCR1CCR5CCR8HDAC6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192668-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE THEREOF | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192668-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE THEREOF | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-11680053-B2 | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-06-20 | — | — | US | disclosed |
| US-11680053-B2 | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-06-20 | — | — | US | disclosed |
| US-20230160904-A1 | REAGENT FOR MASS SPECTROMETRY | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2023-05-25 | — | — | US | disclosed |
| EP-4154009-A1 | REAGENT FOR MASS SPECTROMETRY | F. Hoffmann-La Roche AG (CH) | 2023-03-29 | — | — | EP | disclosed |
| US-11584732-B2 | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-20220220049-A1 | ORGANIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE AND ELECTRONIC APPARATUS | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2022-07-14 | — | — | US | disclosed |
| US-20220056009-A1 | 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS | NXERA PHARMA UK LIMITED (GB) | 2022-02-24 | — | — | US | disclosed |
| US-20210309632-A1 | 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS | NXERA PHARMA UK LIMITED (GB) | 2021-10-07 | — | — | US | disclosed |
| US-20090069435-A1 | Bridged polycyclic compound based compositions for topical applications for pets | ALLACCEM, INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090054402-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054528-A1 | Bridged polycyclic compound based compositions for coating oral surfaces in pets | ALLACCEM, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20080275141-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE | ALLACCEM, INC. | 2008-11-06 | — | — | US | disclosed |
| WO-2008131000-A2 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080207581-A1 | Applying to a surface one or more bridged polycyclic compounds comprising at least two cyclic groups defined in part by quaternary ammonium moieties; microbiocides; self-cleaning | ALLACCEM, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080020127-A1 | Methods and systems for coating a medical device | ALLACCEM, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021212-A1 | Methods and systems for preparing an antimicrobial composition | ALLACCEM, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20070202342-A1 | Applying to an oral surface (teeth or gums)one or more bridged polycyclic compounds comprising at least two cyclic groups defined in part by quaternary ammonium moieties; microbiocides; self-cleaning; dentistry; bonding agents, resin cements, sealants | ALLACCEM, INC. | 2007-08-30 | — | — | US | disclosed |
| US-3931332-A | Stabilized hydroformylation reaction systems | CHEVRON RESEARCH COMPANY (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220049-A1 | ORGANIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE AND ELECTRONIC APPARATUS | HCN2, EPCAM, EFNA1 | CCR1 2265/4885CCR5 1239/4885CCR8 639/4885 |
| US-20090069435-A1 | Bridged polycyclic compound based compositions for topical applications for pets | OTC, SLC16A8, SLC16A7 | CCR1 488/4885CCR5 3248/4885CCR8 225/4885 |
| US-20090054528-A1 | Bridged polycyclic compound based compositions for coating oral surfaces in pets | PAICS, SLC16A8, CAD | CCR1 1245/4885CCR5 4018/4885CCR8 624/4885 |
| US-20230192668-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE THEREOF | XPO4, OR10J3, EPB41 | CCR1 335/4885CCR5 575/4885CCR8 747/4885 |
| US-20080021212-A1 | Methods and systems for preparing an antimicrobial composition | DNMT1, TET2, POLR1C | CCR1 1518/4885CCR5 3749/4885CCR8 1004/4885 |
| US-20080207581-A1 | Applying to a surface one or more bridged polycyclic compounds comprising at least two cyclic groups defined in part by quaternary ammonium moieties; microbiocides; self-cleaning | DNMT1, TET2, CD14 | CCR1 639/4885CCR5 2268/4885CCR8 427/4885 |
| US-11680053-B2 | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | GRM5, GRM2, GRM6 | CCR1 849/4885CCR5 372/4885CCR8 1096/4885 |
| US-11584732-B2 | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | GRM5, GRM2, GRM6 | CCR1 849/4885CCR5 372/4885CCR8 1096/4885 |
| US-20080275141-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE | PKD1, VHL, PKD2 | CCR1 1139/4885CCR5 3700/4885CCR8 1388/4885 |
| US-20230160904-A1 | REAGENT FOR MASS SPECTROMETRY | SRMS, AKR7A2, PTMS | CCR1 3087/4885CCR5 2600/4885CCR8 3057/4885 |
| US-20220056009-A1 | 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS | GRM5, GRM6, GRM2 | CCR1 806/4885CCR5 359/4885CCR8 1175/4885 |
| US-20210309632-A1 | 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS | GRM5, GRM6, GRM2 | CCR1 806/4885CCR5 359/4885CCR8 1175/4885 |
| US-20090054402-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, API5 | CCR1 3615/4885CCR5 2850/4885CCR8 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.